Initial Experience with Proton Beam Therapy for Differentiated Thyroid Cancer
08/06/2021
/
Publications
/
Thyroid
Head and neck
Esophagus
IMPT
This study reported outcomes of 14 patients with recurrent, radioactive iodine (RAI) refractory differentiated thyroid cancer (DTC) treated with IMPT. At 8...
Practice patterns among radiation oncologists treating pediatric patients with proton craniospinal irradiation.
07/07/2019
/
Publications
/
Pediatric
Craniospinal irradiation
Head and neck
Esophagus
Thyroid
This survey study aimed to assess current practice patterns regarding the vertebral bodies (VB) coverage for pediatric patients undergoing CSI. With the 28...
Hypothyroidism after craniospinal irradiation with PT or photon therapy in patients with medulloblastoma.
11/12/2018
/
Publications
/
Pediatric
Thyroid
Hypothyroidism
Craniospinal irradiation
Medulloblastoma
Head and neck
This study reviewed ninety-five patients (54 XRT and 41 PRT) treated with craniospinal irradiation (CSI) who had baseline and yearly follow-up for thyroid...
Comparison of hypothyroidism and adrenal insufficiency in children with medulloblastoma
28/10/2021
/
Publications
/
Pediatric
Thyroid
Medulloblastoma
Craniospinal irradiation
Hypothyroidism
This study compared the incidence of hypothyroidism, growth hormone deficiency (GHD), and adrenal insufficiency (AI) in patients with medulloblastoma following...
Risk of secondary malignant neoplasms in children following proton therapy vs. photon therapy for primary CNS tumors: A systematic review and meta-analysis.
15/11/2022
/
Publications
/
Pediatric
Brain and CNS
Glioma
Sarcomas
Thyroid
This systematic review included 24 studies for analysis in order to compare the incidence of SMNs after proton and photon-based radiation for pediatric CNS...
Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy.
15/11/2022
/
Publications
/
PBT
Overall Survival
Gastrostomy
Thyroid
This retrospective study evaluated 22 patients with thyroid cancer treated with PBT to a total dose of 60 GyRBE adjuvantly and 70 GyRBE for gross disease. With...
Cookies policy
If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.
Manage your cookie preferences
Respect for your privacy is still a priority for us at IBA.
Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.